TY - JOUR
T1 - Cyclosporine metabolism and pharmacokinetics following intravenous and oral administration in the dog
AU - Gridelli, Bruno
AU - Scanlon, Lenia
AU - Pellicci, Riccardo
AU - Lapointe, Real
AU - Dewolf, Andre
AU - Seltman, Howard
AU - Diven, Warren
AU - Shaw, Byers
AU - Starzl, Thomas
AU - Sanghvi, Ajit
PY - 1986/3
Y1 - 1986/3
N2 - The influence of assay method on single dose cyclosporine (CsA) pharmacokinetics was studied in nine dogs receiving either i.v. or oral CsA. Samples were drawn from hepatic, portal, and systemic veins at various times after the dose and CsA levels were determined by radiommunoassay (RIA) and high-performance liquid chromatography (HPLC). Blood concentration-time data were analyzed by nonlinear least-squares regression, using two-compartment models. RIA/HPLC ratios for all samples were greater than one, and did not change significantly over time. The mean RIA/HPLC ratios for samples drawn from all three veins were higher after oral than i.v. doses of the drug (T="I">P<0.05). Area under the concentration-time curve (AUC) was higher and systemic clearance (Cls) lower than calculated on the basis of RIA results, regardless of the route of administration. AUC calculated for CsA metabolites (RIA-HPLC) was highest in the portal vein after an oral dose of CsA. Bioavailability was 20.4% and 27.0% when estimated using HPLC and RIA data, respectively. The mean CsA metabolite index (CMI), when calculated for hepatic, portal, or systemic vein, was greater when the drug was administered orally. The mean hepatic extraction ratio (HER) of the parent drug and for CsA metabolites was approximately 23% in i.v. and p.o. studies. These results suggest that the gastrointestinal tract may play a role in the metabolism of CsA when the drug is administered orally. In addition, if CsA metabolites not measured by HPLC have either toxic or immunosuppressive properties, the RIA assay may be more useful for monitoring patients.
AB - The influence of assay method on single dose cyclosporine (CsA) pharmacokinetics was studied in nine dogs receiving either i.v. or oral CsA. Samples were drawn from hepatic, portal, and systemic veins at various times after the dose and CsA levels were determined by radiommunoassay (RIA) and high-performance liquid chromatography (HPLC). Blood concentration-time data were analyzed by nonlinear least-squares regression, using two-compartment models. RIA/HPLC ratios for all samples were greater than one, and did not change significantly over time. The mean RIA/HPLC ratios for samples drawn from all three veins were higher after oral than i.v. doses of the drug (T="I">P<0.05). Area under the concentration-time curve (AUC) was higher and systemic clearance (Cls) lower than calculated on the basis of RIA results, regardless of the route of administration. AUC calculated for CsA metabolites (RIA-HPLC) was highest in the portal vein after an oral dose of CsA. Bioavailability was 20.4% and 27.0% when estimated using HPLC and RIA data, respectively. The mean CsA metabolite index (CMI), when calculated for hepatic, portal, or systemic vein, was greater when the drug was administered orally. The mean hepatic extraction ratio (HER) of the parent drug and for CsA metabolites was approximately 23% in i.v. and p.o. studies. These results suggest that the gastrointestinal tract may play a role in the metabolism of CsA when the drug is administered orally. In addition, if CsA metabolites not measured by HPLC have either toxic or immunosuppressive properties, the RIA assay may be more useful for monitoring patients.
UR - http://www.scopus.com/inward/record.url?scp=0022623959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022623959&partnerID=8YFLogxK
U2 - 10.1097/00007890-198603000-00021
DO - 10.1097/00007890-198603000-00021
M3 - Article
C2 - 3952805
AN - SCOPUS:0022623959
SN - 0041-1337
VL - 41
SP - 388
EP - 391
JO - Transplantation
JF - Transplantation
IS - 3
ER -